H.C. Wainwright lowered the firm's price target on Neuphoria Therapeutics to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is "caught between a rock and a hard place right now." With the Phase 3 social anxiety disorder failure, Neuphoria's risk profile "has increased significantly," the anlayst tells investors in a research note. However, the firm says the positive Phase 2b post-traumatic stress disorder data still provides value to the company.
